Philip A. Philip, MD

Philip A. Philip, MD, is the director of Gastrointestinal Oncology, co-director of the Pancreatic Cancer Center, and medical director of Research and Clinical Care Integration at the Henry Ford Cancer Institute

Articles by Philip A. Philip, MD

Exploring the FDA Approval of Optune Pax and What It Means for Locally Advanced Pancreatic Cancer

ByPhilip A. Philip, MD

September 28th 2026

Philip A. Philip, MD, discusses TTFields in pancreatic cancer and what phase 3 data has shown in locally advanced disease.

Philip A. Philip, MD

Articles by Philip A. Philip, MD

Exploring the FDA Approval of Optune Pax and What It Means for Locally Advanced Pancreatic Cancer

Latest Updated Articles

Trending on OncLive

Ifinatamab Deruxtecan BLA Voluntarily Withdrawn in Previously Treated Extensive-Stage SCLC

Long-Term PERSEUS Data Confirm Durable PFS Benefit With D-VRd in Transplant-Eligible Newly Diagnosed Myeloma

Five Under 5: Top Oncology Videos for the Week of 9/20

FDA Grants Priority Review to Perioperative Durvalumab Plus Neoadjuvant Enfortumab Vedotin in MIBC

Iberdomide Plus Daratumumab/Dexamethasone Improves MRD-Negative CR vs DVd in Relapsed/Refractory Myeloma